Cargando…
Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
OBJECTIVES: Assessment of the impact of pooling five single‐donor plasma (SDP) units to obtain six pathogen‐reduced therapeutic plasma (PTP) units on standardisation and the retention of labile coagulation factors. BACKGROUND: SDP shows a high inter‐donor variability with potential implications for...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048654/ https://www.ncbi.nlm.nih.gov/pubmed/33686720 http://dx.doi.org/10.1111/tme.12763 |
_version_ | 1783679270438043648 |
---|---|
author | Bubinski, Michal Gronowska, Agnieszka Szykula, Pawel Kluska, Kamila Kuleta, Ilona Ciesielska, Emilia Picard‐Maureau, Marcus Lachert, Elzbieta |
author_facet | Bubinski, Michal Gronowska, Agnieszka Szykula, Pawel Kluska, Kamila Kuleta, Ilona Ciesielska, Emilia Picard‐Maureau, Marcus Lachert, Elzbieta |
author_sort | Bubinski, Michal |
collection | PubMed |
description | OBJECTIVES: Assessment of the impact of pooling five single‐donor plasma (SDP) units to obtain six pathogen‐reduced therapeutic plasma (PTP) units on standardisation and the retention of labile coagulation factors. BACKGROUND: SDP shows a high inter‐donor variability with potential implications for the clinical treatment outcome. Additionally, there is still an existing risk for window‐period transmissions of blood borne pathogens including newly emerging pathogens. METHODS/MATERIALS: Five ABO‐identical SDP units were pooled, treated with the INTERTCEPT™ Blood System (Cerus Corporation, U.S.A.) and split into six PTP units which were frozen and thawed after 30 days. The variability in volume, labile coagulation factor retention and activity was assessed. RESULTS: The variability of volumes between the PTP units was reduced by 46% compared to SDP units. The variability in coagulation factor content between the PTP units was reduced by 63% compared to SDP units. Moderate, but significant losses of coagulation factors (except for vWF) were observed in PTPs compared to SDPs. CONCLUSION: The pooling of five SDP units to obtain six PTP units significantly increases product standardisation with potential implications for safety, economics as well as transfusion‐transmitted pathogen safety, making it an interesting alternative to quarantine SDP (qSDP) and pathogen‐reduced SDP. |
format | Online Article Text |
id | pubmed-8048654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-80486542021-04-19 Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units Bubinski, Michal Gronowska, Agnieszka Szykula, Pawel Kluska, Kamila Kuleta, Ilona Ciesielska, Emilia Picard‐Maureau, Marcus Lachert, Elzbieta Transfus Med Short Communications OBJECTIVES: Assessment of the impact of pooling five single‐donor plasma (SDP) units to obtain six pathogen‐reduced therapeutic plasma (PTP) units on standardisation and the retention of labile coagulation factors. BACKGROUND: SDP shows a high inter‐donor variability with potential implications for the clinical treatment outcome. Additionally, there is still an existing risk for window‐period transmissions of blood borne pathogens including newly emerging pathogens. METHODS/MATERIALS: Five ABO‐identical SDP units were pooled, treated with the INTERTCEPT™ Blood System (Cerus Corporation, U.S.A.) and split into six PTP units which were frozen and thawed after 30 days. The variability in volume, labile coagulation factor retention and activity was assessed. RESULTS: The variability of volumes between the PTP units was reduced by 46% compared to SDP units. The variability in coagulation factor content between the PTP units was reduced by 63% compared to SDP units. Moderate, but significant losses of coagulation factors (except for vWF) were observed in PTPs compared to SDPs. CONCLUSION: The pooling of five SDP units to obtain six PTP units significantly increases product standardisation with potential implications for safety, economics as well as transfusion‐transmitted pathogen safety, making it an interesting alternative to quarantine SDP (qSDP) and pathogen‐reduced SDP. Blackwell Publishing Ltd 2021-03-08 2021-04 /pmc/articles/PMC8048654/ /pubmed/33686720 http://dx.doi.org/10.1111/tme.12763 Text en © 2021 The Authors. Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communications Bubinski, Michal Gronowska, Agnieszka Szykula, Pawel Kluska, Kamila Kuleta, Ilona Ciesielska, Emilia Picard‐Maureau, Marcus Lachert, Elzbieta Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units |
title | Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units |
title_full | Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units |
title_fullStr | Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units |
title_full_unstemmed | Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units |
title_short | Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units |
title_sort | plasma pooling in combination with amotosalen/uva pathogen inactivation to increase standardisation and safety of therapeutic plasma units |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048654/ https://www.ncbi.nlm.nih.gov/pubmed/33686720 http://dx.doi.org/10.1111/tme.12763 |
work_keys_str_mv | AT bubinskimichal plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits AT gronowskaagnieszka plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits AT szykulapawel plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits AT kluskakamila plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits AT kuletailona plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits AT ciesielskaemilia plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits AT picardmaureaumarcus plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits AT lachertelzbieta plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits |